<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021900</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-2101</org_study_id>
    <nct_id>NCT05021900</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II, Multi-center, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and&#xD;
      safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients without disease progression</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>It is defined as sum of CR and PR rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>2 years</time_frame>
    <description>It is defined as sum of CR, PR and SD rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS).</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is measured from the time of first dose of study drug to radiographic documentation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tenalisib 800 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenalisib 1200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib will be administered 800mg BID, orally</description>
    <arm_group_label>Tenalisib 800 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib will be administered 1200mg BID, orally</description>
    <arm_group_label>Tenalisib 1200 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be ≥18 years of age, at the time of signing informed consent.&#xD;
&#xD;
          2. Female patients who have histologically and/or cytologically confirmed locally&#xD;
             advanced or metastatic breast cancer that has progressed following at least one line&#xD;
             of therapy.&#xD;
&#xD;
          3. Patients with at least one measurable lesion per RECIST version 1.1 at baseline that&#xD;
             can be accurately assessed by CT scan or MRI and is suitable for repeated assessment&#xD;
             at follow up-visits.&#xD;
&#xD;
          4. ECOG performance status 0 to 2.&#xD;
&#xD;
          5. Life expectancy of at least 3 months.&#xD;
&#xD;
          6. Adequate bone marrow, liver, and renal functions&#xD;
&#xD;
          7. Female patients of childbearing potential should be willing to use a medically&#xD;
             acceptable method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with HER-2 positive breast cancer.&#xD;
&#xD;
          2. Patients receiving anticancer therapy within 4 weeks or 5 half-lives of the drug prior&#xD;
             to C1D1, whichever is shorter.&#xD;
&#xD;
          3. Patient who has not recovered from acute toxicities (defined as NCI-CTCAE grade &gt; 1)&#xD;
             of previous therapy except treatment-related alopecia.&#xD;
&#xD;
          4. Patients who have had disease progression within 8 weeks of platinum chemotherapy.&#xD;
&#xD;
          5. Prior exposure to investigational or marketed PI3K inhibitors given for the treatment&#xD;
             of breast cancer.&#xD;
&#xD;
          6. Major surgery within 4 weeks of starting study treatment OR any patient who has not&#xD;
             recovered from the effects of major surgery.&#xD;
&#xD;
          7. Patient with symptomatic uncontrolled brain metastasis.&#xD;
&#xD;
          8. HIV-positive patients who are on antiretroviral therapy OR active hepatitis C OR&#xD;
             active hepatitis B virus infections.&#xD;
&#xD;
          9. Ongoing immunosuppressive therapy including systemic corticosteroids except as allowed&#xD;
             per concomitant medication.&#xD;
&#xD;
         10. Known history of severe liver injury as judged by the investigator.&#xD;
&#xD;
         11. History of severe cutaneous reactions in the past.&#xD;
&#xD;
         12. Active gastrointestinal tract disease with malabsorption syndrome or uncontrolled&#xD;
             inflammatory gastrointestinal disease such as Crohn's disease or ulcerative colitis.&#xD;
&#xD;
         13. Pregnancy or lactation.&#xD;
&#xD;
         14. Patient with other active malignancies at the time of screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prajak Barde</last_name>
    <phone>+41325800175</phone>
    <email>pjb@rhizen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>High Technology Hospital Medcenter</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamta Makharadze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC Caucasus Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivane Kiladze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simon Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgi Dzagnidze</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RP6530</keyword>
  <keyword>Tenalisib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

